We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Precision BioSciences
DTIL
$207M
| $556K | ﹤0.01% |
1,606
+78
| +5% | +$26.4K |
|
2502
Business First Bancshares
BFST
$1.03B
| $554K | ﹤0.01% |
23,680
+270
| +1% | +$6.26K |
|
|
CTLP
2503
DELISTED
Cantaloupe
CTLP
| $547K | ﹤0.01% |
50,781
+2,646
| +5% | +$27.4K |
|
2504
Global Industrial
GIC
$1.49B
| $546K | ﹤0.01% |
14,405
+363
| +3% | +$13.6K |
|
|
AERI
2505
DELISTED
Aerie Pharmaceuticals
AERI
| $546K | ﹤0.01% |
47,933
+2,053
| +4% | +$30K |
|
|
BTRS
2506
DELISTED
BTRS Holdings Inc. Class 1 Common Stock
BTRS
| $542K | ﹤0.01% |
50,966
+9,809
| +24% | +$113K |
|
2507
Alerus Financial
ALRS
$828M
| $538K | ﹤0.01% |
18,007
+410
| +2% | +$11.8K |
|
2508
Daily Journal
DJCO
$778M
| $536K | ﹤0.01% |
1,674
+62
| +4% | +$20.3K |
|
2509
Geron
GERN
$949M
| $536K | ﹤0.01% |
391,307
+9,007
| +2% | +$12K |
|
2510
Citizens & Northern Corp
CZNC
$455M
| $534K | ﹤0.01% |
21,142
+1,045
| +5% | +$26K |
|
|
ZYXI
2511
DELISTED
Zynex
ZYXI
| $534K | ﹤0.01% |
51,578
-7,285
| -12% | -$93.6K |
|
2512
American Superconductor
AMSC
$1.59B
| $533K | ﹤0.01% |
36,523
+1,380
| +4% | +$19.1K |
|
|
IGMS
2513
DELISTED
IGM Biosciences
IGMS
| $530K | ﹤0.01% |
8,056
+361
| +5% | +$27.6K |
|
2514
Old Second Bancorp
OSBC
$1.29B
| $530K | ﹤0.01% |
40,550
+802
| +2% | +$9.63K |
|
2515
Astronics
ATRO
$3.84B
| $529K | ﹤0.01% |
45,154
+1,196
| +3% | +$15.2K |
|
2516
Greif Class B
GEF.B
$4.21B
| $529K | ﹤0.01% |
8,169
+156
| +2% | +$9.59K |
|
|
VAPO
2517
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $527K | ﹤0.01% |
2,957
+125
| +4% | +$25.4K |
|
|
RAPT
2518
DELISTED
RAPT Therapeutics
RAPT
| $525K | ﹤0.01% |
2,112
+137
| +7% | +$36.2K |
|
2519
Stagwell
STGW
$2.24B
| $524K | ﹤0.01% |
68,347
+10,009
| +17% | +$66.8K |
|
2520
Verastem
VSTM
$610M
| $524K | ﹤0.01% |
14,186
+564
| +4% | +$20.7K |
|
|
KDNY
2521
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $524K | ﹤0.01% |
41,083
+1,695
| +4% | +$22.3K |
|
2522
Altimmune
ALT
$599M
| $522K | ﹤0.01% |
46,182
+4,021
| +10% | +$48.9K |
|
2523
Nuvation Bio
NUVB
$2.32B
| $521K | ﹤0.01% |
52,377
+17,730
| +51% | +$161K |
|
|
SPNE
2524
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $521K | ﹤0.01% |
33,101
+1,475
| +5% | +$25.2K |
|
2525
Southern First Bancshares
SFST
$600M
| $518K | ﹤0.01% |
9,690
+59
| +0.6% | +$2.98K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.